IL1B and steatosis: In addition, BAR502 effectively reduced liver fat accumulation, as measured by assessing the steatosis score, inflammation, as measured by assessing the inflammatory score as well as expression of inflammatory biomarkers such as Il-1β, Il-6, Tnfα, and F4/80, and severity of liver fibrosis, assessed by measuring the fibrosis score, as well as the expression of markers of extracellular matrix deposition including Col1α, αSma, and Tgfβ (Figure 2 and Figure 3).